Tetracyclines for the treatment of rheumatoid arthritis

Bibliography

• GREENWALD RA: Tetracyclines may be therapeuticallybeneficial in rheumatoid arthritis, but not for the reasons that you think. J. Clin. Rheumatol. (1995) 3:190–193.
   Google Scholar
• ALARCON GS, MIKHAIL IS: Antimicrobials in thetreatment of rheumatoid arthritis and other arthri-tides: A clinical perspective. Am. J. Med. ScL (1994) 308:201–209.
   PubMed Web of Science ®Google Scholar
• ALARCON GS: Antibiotics for the treatment ofrheumatic disease. Clin. Rheumatol. (1995) 5:1–6.
   Google Scholar
• SANCHEZ I: As tetraciclinas no tratamento da artritereumatoide e doencas reumaticas inflamatorias. [Tetracycline treatment in rheumatoid arthritis and other rheumatic diseases]. Brasil Med. (1968) 82:22–31.
   Google Scholar
• BARTHOLOMEW LE: Isolation and characterization of mycoplasmas (PPLO) from patients with rheumatoid arthritis, systemic lupus erythematosus and Reiter's syndrome. Arthritis Rheum. (1965) 8:376–388.
   PubMed Web of Science ®Google Scholar
• DAVIS CP, COCHRAN S, LISSE J et al.: Isolation of mycoplasma pneumoniae from synovial fluid samples in a patient with pneumonia and polyarthritis. Arch. Intern. Med. (1988) 148:969–970.
   PubMed Web of Science ®Google Scholar
• WILLIAMS MH, BROSTOFF J, ROITT IM: Possible role of mycoplasma fermentans in pathogenesis of rheuma-toid arthritis. Lancet (1970):277–280.
   PubMed Web of Science ®Google Scholar
• BROWN TM, OLIVER C, CHARBONNET P: Ongoing treatment with antibiotics. The Scanner (1992):1–4.
   Google Scholar
• HAIER J, NASRALLA M, FRANCO AR, NICOLSON GL: Detection of mycoplasmal infections in blood of patients with rheumatoid arthritis. Rheumatology (1999) 38:504–509.
   PubMed Web of Science ®Google Scholar
• BROWN TM, HOCHBERG MC, HICKS JT, CLARK HW: Antibiotic therapy of rheumatoid arthritis: A retrospective cohort study of 98 patients with 451 patient-years of follow-up. (Proceedings of Meeting). InL Con. Rheumatol. (1985):S85.
   Google Scholar
• SKINNER M, CATHCART ES, MILLS JA, PINALS RS: Tetracy-cline in the treatment of rheumatoid arthritis. A double blind controlled study. Arthritis Rheum. (1971) 14:727–732.
   PubMed Web of Science ®Google Scholar
• STEERE AC, MALAWISTA SE, SNYDMAN DR et al.: Lymearthritis. An epidemic of oligoarticular arthritis in children and adults in three Connecticut communi-ties. Arthritis Rheum. (1977) 20:7–17.
   PubMed Web of Science ®Google Scholar
• GOLUB LM, MCNAMARA TF, D'ANGELO G, GREENWALDRA, RAMAMURTHY NS: A nonantibacterial chemically modified tetracycline inhibits mammalian collage-nase activity. J. Dent. Res. (1987) 66:1310–1314.
   PubMed Web of Science ®Google Scholar
• GOLUB LM, EVANS RT, MCNAMARA TF, LEE HM, RAMAMURTHY NS: A non-antimicrobial tetracycline inhibits gingival matrix metalloproteinases and bone loss in Porphyromonas gingivalis induced periodon-titis in rats. Ann. NY Acad. Sci. (1994) 732:96–111.
   PubMed Web of Science ®Google Scholar
• GOLUB LM, SUOMALAINEN K, SORSA T: Host modula-tion with tetracyclines and their chemically modified analogues. Curr. Opin. Den. (1992):80–90.
   PubMedGoogle Scholar
• LANGEVITZ P, BANK I, ZEMER D, BOOK M, PRAS M: Treatment of resistant rheumatoid arthritis with minocycline: An open study. J. Rheumatol. (1992) 19:1502–1504.
   PubMed Web of Science ®Google Scholar
• BREEDVELD FC, DIJKMANS BAC, MATTIE H: Minocyclinetreatment for rheumatoid arthritis: An open dose finding study. J. Rheumatol (1990) 17:43–46.
   PubMed Web of Science ®Google Scholar
• KLOPPENBURG M, BREEDVELD FC, TERWIEL JP, MALLEEC, DIJKMANS AC: Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum. (1994) 37:629–636.
   PubMed Web of Science ®Google Scholar
• TILLEY BC, ALARCON GS, HEYSE SP et al. FOR THE MIRATRIAL GROUP M: Minocycline in rheumatoid arthritis: A 48 week, double-blind, placebo-controlled trial. Ann. Intern. Med. (1995) 122:81–89.
   PubMed Web of Science ®Google Scholar
• O'DELL JR, HAIRE CE, PALMER W et al.: Treatment ofearly rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo- controlled trial. Arthritis Rheum. (1997) 40:842–848.
   Google Scholar
• SIGAL LH: Antimicrobials. In Complementary andAlternative Therapies for Rheumatic Disease. Panush RS (Ed), Rheumology Clinical, USA (1999):861–881.
   Google Scholar
• GOLUB LM, WOLFF M, LEE HM: Further evidence thattetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J. Periodontal Res. (1985) 20:12–23.
   PubMed Web of Science ®Google Scholar
• GOLUB LM: Reduction with tetracyclines of excessivecollagen degradation in periodontal and other diseases. New York St. Dental J. (1990) 56:24–26.
   PubMedGoogle Scholar
• RYAN ME, GREENWALD RA, GOLUB LM: Potential of tetracyclines to modify cartilage breakdown in osteoarthritis. Curr. Opin. Rheumatol. (1996) 8:238–247.
   PubMedGoogle Scholar
• AMIN AR, ATTUR MG, THAKKER GD et al.: A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases. Proc. Natl. Acad. Sci. USA (1996) 93:14014–14019.
   PubMed Web of Science ®Google Scholar
• YU LPJ, SMITH GNJ, BRANDT KD, MYERS SL, O'CONNOR BL, BRANDT DA: Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum. (1992) 35:1150–1159.
   PubMed Web of Science ®Google Scholar
• YU LPJ, SMITH GNJ, HASTY KA, BRANDT KD: Doxycyline inhibits type XI collagenolytic activity of extracts from human osteoarthritic cartilage and of gelatinase. J. Rheumatol. (1991) 18:1450–1452.
   PubMed Web of Science ®Google Scholar
• PRUZANSKI W, GREENWALD RA, STREET IP et al.: Inhibi-tion of enzymatic activity of phospholipases A2 by minocycline and doxycycline. Biochem. Pharmacol. (1992) 44:1165–1170.
   PubMed Web of Science ®Google Scholar
• GREENWALD RA, MOAK SA, RAMAMURTHY NS, GOLUB LM: Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J. Rheumatol. (1992) 19:927–938.
   PubMed Web of Science ®Google Scholar
• SUOMALAINEN K, SORSA T, GOLUB LM et al.: Specificity of the anticollagenase action of tetracyclines: Relevance to their anti-inflammatory potential. Antimicrob. Agents Chemother. (1992) 36:227–229.
   PubMed Web of Science ®Google Scholar
• GREENWALD RA: Collagenase inhibitors, tetracyclines and the potential for mediating the degradation of connective tissue. Medguide Inflamm. Dis. (1988) 7:3–4.
   Google Scholar
• GREENWALD RA, GOLUB LM, LAVIETES B et al.: Tetracy-clines inhibit human synovial collagenase in vitro and in vitro. J. Rheumatol. (1987) 14:28–32.
   PubMed Web of Science ®Google Scholar
• DONAHUE HJ, IIJIMA K, GOLIGORSKY MS, RUBIN CT, RIFKIN BR: Regulation of cytoplasmic calcium concen-tration in tetracycline-treated osteoclasts. J. Bone Miner. Res. (1992) 7:1313–1318.
   PubMed Web of Science ®Google Scholar
• PAEMEN L, MARTENS E, NORGA K et al.: The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem. Pharmacol. (1996) 52:105–111.
   PubMed Web of Science ®Google Scholar
• GOLUB LM, RAMAMURTHY NS, MCNAMARA TF et al:Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease. J. Periodontal Res. (1984) 19:651–655.
   PubMed Web of Science ®Google Scholar
• GOLUB LM, GREENWALD R, RAMAMURTHY NS, ZUCKERS, RAMSAMMY L, MCNAMARA T: Tetracyclines inhibit matrix metalloproteinases: in vivo effects in arthritic and diabetic rats and new in vitro studies. Matrix (1992) S1:315–316.
   Google Scholar
• GREENWALD RA, MOAK SA, GOLUB LM: Low dose doxycycline (LDD) inhibits pyridinoline (PYD) excretion in selected patients with rheumatoid arthritis. In: Inhibition of matrix metalloproteinase: therapeutic potential. Ann. NY Acad. Sci. (1994) 732:419–421.
   PubMed Web of Science ®Google Scholar
• SE WELL KL, BREEDVELD F, FURRIE E et al: The effect ofminocycline in rat models of inflammatory arthritis: Correlation of arthritis suppression with enhanced T cell calcium flux. Cell. Immunol. (1996) 167:195–204.
   PubMed Web of Science ®Google Scholar
• KLOPPENBURG M, MATTIE H, DOUWES N, DIJKMANS BA,BREEDVELD FC: Minocycline in the treatment of rheumatoid arthritis: relationship of serum concen-trations to efficacy. J. Rheumatol. (1995) 22:611–616.
   PubMed Web of Science ®Google Scholar
• ELEWSKI BE, LAMB BAJ, SAMS WMJ, GAMMON WR: Invivo suppression of neutrophil chemotaxis by systemically and topically administered tetracycline. J. Am. Acad. Dermatol. (1983) 8:807–812.
   PubMed Web of Science ®Google Scholar
• GABLER WL, CREAMER HR: Suppression of human neutrophil functions by tetracyclines. J. Periodontal Res. (1991) 26:52–58.
   PubMed Web of Science ®Google Scholar
• THONG YH, FERRANTE A: Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues. Clin. Exp. Immunol. (1979) 35:443–446.
   PubMed Web of Science ®Google Scholar
• KLOPPENBURG M, MILTENBURG AMM, VERDONK MJA, DAHA MR, BREEDVELD FC, DIJKMAUS BAC: Minocycline inhibits T cell proliferation and interferon gamma (IFN-gamma) production after stimulation with anti-CD3 monoclonal antibodies. Br. J. Rheumatol. (1992) 31:S41 (Abstract) .
   Google Scholar
• BRANDT KD: Toward pharmacologic modification of joint damage in osteoarthritis. Ann. Intern. Med. (1995) 122:874–875.
   PubMed Web of Science ®Google Scholar
• FELSON DT: Epidemiology of hip and knee osteoar-thritis. [Review]. Epidemiol. Rev. (1988) 10:1–28.
   PubMed Web of Science ®Google Scholar
• CHENE G: Trials evaluating antibiotics in rheumatoid arthritis: an overview. Rev. Rheum. (1999) 66:67S–72S.
   Google Scholar
• ALARCON GS: Minocycline for the treatment of rheumatoid arthritis. Rheum. Dis. Clin. N Am. (1998) 24:489–499.
   PubMed Web of Science ®Google Scholar
• O'DELL J, PALMER W, CHURCHILL M, BLAKLEY K, WEES S, ECKHOFF J: Minocycline therapy for early rheumatoid arthritis (RA): continued efficacy at three years. Arthritis Rheum. (1997) 40:S219 (Abstract).
   Google Scholar
• HARRIS EDJ: Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl. J. Med. (1990) 322:1277–1289.
   PubMed Web of Science ®Google Scholar
• SITBON O, BIDEL N, DUSSOPT C et al.: Minocycline pneumonitis and eosinophilia. A report on eight patients. Arch. Intern. Med. (1994) 154:1633–1640.
   PubMed Web of Science ®Google Scholar
• SHIRI J, AMICHAI B: Intracranial hypertension and minocycline. Ann. Intern. Med. (1997) 127:168.
   PubMed Web of Science ®Google Scholar
• THIBAULT M, BILLICK RC, SROLOVITZ H: Minocycline-induced Sweet's syndrome. J. Am. Acad. Dermatol (1992) 27:801–804.
   PubMed Web of Science ®Google Scholar
• GUILLON JM, JOLY P, AUTRAN B et al.: Minocycline-induced cell-mediated hypersensitivity pneumonitis. Ann. Intern. Med. (1992) 117:476–481.
   PubMed Web of Science ®Google Scholar
• CHRISTODOULOU CS, EMMANUEL P, RAY RA, GOOD RA,SCHNAPF BM, CAWKWELL GD: Respiratory distress due to minocycline-induced pulmonary lupus. Chest (1999) 115:1471–1473.
   PubMed Web of Science ®Google Scholar
• BURETTE A, FINET C, PRIGOGINE T, DE ROY G,DELTENRE M: Acute hepatic injury associated with minocyline. Arch. Intern. Med. (1984) 144:1491–1492.
   PubMedGoogle Scholar
• WALKER RG, THOMSON NM, DOWLING JP, OGG CS: Minocycline-induced acute interstitial nephritis. Br. Med. J. (1979) 1(6162):524.
   PubMed Web of Science ®Google Scholar
• GOUGH A, CHAPMAN S, WAGSTAFF K, EMERY P, ELIAS E: Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. Br. Med. J. (1996) 312:169–172.
   PubMed Web of Science ®Google Scholar
• AKIN E, MILLER LC, TUCKER LB, SCHALLER JG: Minocycline related lupus-like syndrome: posible association with anti-neutrophil cytoplasmic antibodies. Arthritis Rheum. (1997) 40:S191.
   Google Scholar
• ELKAYAM O, LEVARTOVSKY D, BRAUTBAR C et al: Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. Am. J. Med. (1998) 105:484–487.
   PubMed Web of Science ®Google Scholar
• KNIGHTS SE, LEANDRO MJ, KHAMASHTA MA, HUGHES GRV: Minocycline induced lupus. Arthritis Rheum. (1997) 40:S107 (Abstract).
   Google Scholar
• WASEL NR, SCHLOSS EH, UN AN: Minocycline-induced cutaneous pigmentation. J. Cutan. Med. Surg. (1998) 3:105–108.
   PubMedGoogle Scholar
• WESTBURY LW, NAJERA A: Minocycline-induced intraoral pharmacogenic pigmentation: case reports and review of the literature. J. Periodontol. (1997) 68:84–91.
   PubMed Web of Science ®Google Scholar
• RUMBAK MJ, PITCOCK JA, PALMIERI GMA, ROBERTSON JT: Black bones following long-term minocycline treatment. Arch. Pathol. Lab. Med. (1991) 115:939–941.
   PubMed Web of Science ®Google Scholar
• FENSKE NA, MILLNS JL, GREER KE: Minocycline-induced pigmentation at sites of cutaneous inflammation. J. Am. Med. Assoc. (1980) 24:1103–1106.
   Google Scholar
• ANGELONI VL, SALASCHE SJ, ORTIZ R: Nail, skin and scleral pigmentation induced by minocycline. Cutts (1987) 40:229–234.
   PubMed Web of Science ®Google Scholar
• RIDGWAY HB, REIZNER GT: Acquired pseudo-mongolian spot associated with minocycline therapy. Arch. Dermatol. (1992) 128:565.
   PubMed Web of Science ®Google Scholar
• O'DELL JR, PAULSEN G, HAIRE CE et al.: Treatment of early seropositive rheumatoid arthritis with minocy-line: four-year followup of a double-blind, placebo-controlled trial. Arthritis Rheum. (1999) 42:1691–1695.
   Google Scholar
• HARRIS EDJ: Antibiotics and other novel therapies. In Rheumatoid Arthritis. Harris ED Jr. (Ed.), W.B. Saunders, Philadelphia, USA (1997):415–417.
   Google Scholar
• PANUSH RS, THOBURN R: Should minocycline be used to treat rheumatoid arthritis? Bull. Rheum. Dis. (1996) 45:2–5.
   Web of Science ®Google Scholar
• PAULUS HE: Minocycline treatment of rheumatoid arthritis. Ann. Intern. Med. (1995) 122:147–148.
   PubMed Web of Science ®Google Scholar
• TOUSSIROT E, DESPAUX J, WENDLING D: Do minocycline and other tetracyclines have a place in rheumatology? Rev. Rhuma. (English) (1997) 64:474–480.
   PubMed Web of Science ®Google Scholar
• KIM NM, FREEMAN CD: Minocycline for rheumatoid arthritis. Ann. Pharmacother. (2000) 29:186–187.
   Google Scholar
• BORIGINI MJ, PAULUS HE: Innovative treatment approaches for rheumatoid arthritis. Combination therapy. Baillieres Chin. Rheumatol (1995) 9:689–710.
   PubMed Web of Science ®Google Scholar
• BREEDVELD FC: Minocycline in rheumatoid arthritis [editorial; comment]. Arthritis Rheum. (1997) 40:794–796.
   PubMed Web of Science ®Google Scholar
• BLUHM GB, SHARP JT, TILLEY B et al.: Radiographic results from the minocycline in rheumatoid arthritis trial (MIRA). J. Rheumatol (1997) 24:1295–1302.
   PubMed Web of Science ®Google Scholar
• REVEILLE JD, ALARCON GS, FOWLER SE et al.: HLA-DRB1genes and disease severity in rheumatoid arthritis. Arthritis Rheum. (1996) 39:1802–1807.
   PubMed Web of Science ®Google Scholar
• LAI NS, LAN JL: Treatment of DMARDs-resistantrheumatoid arthritis with minocycline: a local experi-ence among the Chinese. RheumatoL Int. (1998) 17:245–247.
   PubMed Web of Science ®Google Scholar
• KAWANAKA N, YAMAMURA M, HASHIMOTO H et al.: An evaluation of efficacy of minocycline as an anti-rheumatic drug in patients with active and refrac-tory rheumatoid arthritis. Ryumachi (1998) 38:801–809.
   PubMedGoogle Scholar
• COOPER SM: A perspective on the use of minocycline for rheumatoid arthritis. J. Chin. Rheumatol. (1999) 5:233–238.
   PubMed Web of Science ®Google Scholar
• TRENTHAM DE, DYNESIUS-TRENTHAM R: Antibiotic therapy for rheumatoid arthritis. Scientific and anecdotal appraisals. Rheum. Dis. Chin. N Am. (1995) 21:817–834.
   Google Scholar
• MORELAND LW, FLEISCHMANN RM, FOR THE LEFLUNOMIDE RA INVESTIGATORS GROUP, STRAND V: Efficacy of leflunomide vs. placebo vs. methotrexate in early and late rheumatoid arthritis. Arthritis Rheum. (1998) 41:S155.
   Google Scholar
• MORELAND LW: Inhibitors of tumor necrosis factor forrheumatoid arthritis. J. Rheumatol (1999) 57:7–15.
   Google Scholar